Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 20/20 | 0.72 |
| ▸ | AKT2 | P31751 | 10/20 | 0.72 |
| ▸ | AKT3 | Q9Y243 | 6/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12420184 | 0.90 | AKT1 (0.76) | AKT1AKT2AKT3 | |
| SCHEMBL12420186 | 0.89 | AKT1 (0.76) | AKT1AKT2AKT3 | |
| SCHEMBL2174277 | 0.89 | AKT1 (0.75) | AKT1AKT2AKT3 | |
| SCHEMBL30815163 | 0.86 | AKT1 (0.82) | AKT1AKT2AKT3 | |
| SCHEMBL27226003 | 0.86 | AKT1 (0.82) | AKT1AKT2AKT3 | |
| SCHEMBL2176115 | 0.85 | AKT1 (0.68) | AKT1AKT2AKT3 | |
| SCHEMBL2191672 | 0.84 | AKT1 (1.00) | AKT1AKT2AKT3 | |
| SCHEMBL25384085 | 0.84 | AKT1 (0.71) | AKT1AKT2AKT3 | |
| SCHEMBL30802345 | 0.84 | AKT1 (0.85) | AKT1AKT2AKT3 | |
| SCHEMBL2175128 | 0.84 | AKT1 (0.85) | AKT1AKT2AKT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2519522-B1 | SUBSTITUTED IMIDAZOPYRIDINYL-AMINOPYRIDINE COMPOUNDS | ARQULE INC (US) | 2014-09-24 | — | — | EP | disclosed |
| US-8501770-B2 | Substituted imidazopyridinyl-aminopyridine compounds | ARQULE, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| EP-2519522-A2 | SUBSTITUTED IMIDAZOPYRIDINYL-AMINOPYRIDINE COMPOUNDS | ArQule, Inc. (US) | 2012-11-07 | — | — | EP | disclosed |
| US-20110172203-A1 | Substituted Imidazopyridinyl-Aminopyridine Compounds | ARQULE, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| WO-2011082270-A2 | SUBSTITUTED IMIDAZOPYRIDINYL-AMINOPYRIDINE COMPOUNDS | ARQULE. INC. (US) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172203-A1 | Substituted Imidazopyridinyl-Aminopyridine Compounds | MKI67, CDK4, ABL1 | AKT1 2285/4885AKT2 1216/4885AKT3 1380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.